A stomach illness outbreak at the University of Guelph is part of a trend that has experts noticing a rise in stomach bugs causing vomiting and diarrhea.
Moderna, Inc. (NASDAQ:MRNA – Get Free Report) fell 8.9% on Wednesday after UBS Group lowered their price target on the stock from $108.00 to $96.00. UBS Group currently has a buy rating on the stock.
There’s currently no approved vaccine for norovirus, although Moderna has begun a phase three trial in the U.S. for a vaccine using mRNA technology and aims to test it in 25,000 adults worldwide.
Some results have been hidden because they may be inaccessible to you